Literature DB >> 56999

Radioimmunoassay of bleomycin.

A Broughton, J E Strong.   

Abstract

A radioimmunoassay for bleomycin has been produced using 125l-labeled bleomycin and antisera raised in rabbits against a carbodiimide-catalyzed bleomycin-bovine serum albumin conjugate. 125l-Labeled bleomycin was synthesized by direct iodination of the drug using the chloramine-T technique. The standard curve of the assay was linear on a logit-log plot and the lower limit of sensitivity was 250 pg bleomycin sulfate. A mean recovery of 102.6% (+/- 3.3% S.E.) was obtained using bleomycin added to normal sera. No significant decrease in bleomycin immunoreactivity was observed following 24 hr incubation of the drug in serum at 37 degrees. The radioimmunoassay was also suitable for measuring bleomycin in the presence of other drugs since the assay was not significantly affected by the other antineoplastic agents tested. The sensitivity and specificity of the radioimmunoassay for bleomycin should provide a new means for pharmacokinetic and toxicity studies of bleomycin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56999

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  A radioimmunoassay procedure for tallysomycin S10b in human plasma and urine.

Authors:  R C Gaver; C W Dixon; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Bleomycin pharmacokinetics in man. I. Intravenous administration.

Authors:  D S Alberts; H S Chen; R Liu; K J Himmelstein; M Mayersohn; D Perrier; J Gross; T Moon; A Broughton; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 3.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 4.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

5.  A pharmacokinetic evaluation of IM administration of bleomycin oil suspension.

Authors:  M Davy; E Paus; G Lehne
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  High-performance liquid chromatography assay of bleomycin in human plasma and rat hepatocytes in culture.

Authors:  R Mahdadi; A Kenani; N Pommery; J Pommery; J P Hénichart; M Lhermitte
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 7.  Mechanisms of bleomycin-induced lung damage.

Authors:  J Hay; S Shahzeidi; G Laurent
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

8.  Clinical pharmacology of the anticancer polypeptide neocarzinostatin.

Authors:  S W Hall; J Knight; A Broughton; R S Benjamin; E McKelvey
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Bleomycin clinical pharmacology by radioimmunoassay.

Authors:  S W Hall; J E Strong; A Broughton; M L Frazier; R S Benjamin
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration.

Authors:  Y M Peng; D S Alberts; H S Chen; N Mason; T E Moon
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.